Diamedica Therapeutics Inc Net Income per Employee (DMAC), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Diamedica Therapeutics Inc   (NASDAQ: DMAC)
 

Diamedica Therapeutics Inc Net Income per Employee

DMAC's Quarterly Results, Trends, Rankings, Statistics
Diamedica Therapeutics Inc recorded a cumulative net loss of $-38 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 219 other companies achieving higher income per employee. While Diamedica Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 3561 to 3685.


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DMAC Net Income per Employee (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -1,072,600 -1,002,886 -936,171 -912,171 -845,143
DMAC's Total Ranking # 3685 # 3561 # 3474 # 3358 # 3184
Seq. Net Income Change - - - - -

DMAC Company Profile >> Back to DMAC Efficiency Comparisons >> Compare DMAC Net Income per Employee to its Competitors

DMAC Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 220
Healthcare Sector # 588
Overall Market # 3685

Net Income per Employee Statistics
High Average Low
$ -280,629 $ -541,313 $ -1,072,600
(Mar 31 2020)   (Jun 30 2026)




  News about Diamedica Therapeutics Inc Income per employee

Groundbreaking Progress in Preeclampsia Treatment DiaMedica Therapeutics Unveils Promising Phase 2 Results for DM199

In a significant advancement for women s health, DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company based in Minneapolis, has reported compelling interim results from Part 1a of its Phase 2 clinical trial investigating DM199 (rinvecalinase alfa) for the treatment of preeclampsia. This interim analysis not only met but exceeded pre-specified safety and efficacy endpoints, signifying a noteworthy step forward in addressing this often-overlooked complication of pregnancy.Preeclampsia, characterized by high blood pressure and potential organ damage in pregnant women, affects approximately 5-8% of pregnancies worldwide. It poses serious risks for both mothers and newborns, making effective management critical. Current treatment options are limited, typically revolving around monitoring and the delivery of the baby. Therefore, innovative therapies that can mitigate blood pressure elevations without adversely affecting placental health are urgently needed.




Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2026Number of Employees Jun 30 2026


Date modified: 2026-08-14T05:17:36+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.